$RSII READ THIS NOW, ESPECIALLY THE LAST PARAGRAPH! FROM

New Post Public Reply Private Reply Replies (0) Message Board
southswell
263
$RSII READ THIS NOW, ESPECIALLY THE LAST PARAGRAPH! FROM STOCKROCKET!!!

ALL READ THIS>RSII business model imo:

I should know... Im in the pharmaceutical industry as mgr with a big pharma co.

"Our team has met with business operators that have real experience and expertise in multiple states and several business verticals within the cannabis industry," commented Management. "The business focus will center on working with physicians and pharmacists groups on the Research and Development of new, cutting edge treatments within the medical cannabis industry. Shareholders are encouraged to stay tuned to upcoming press releases and social media updates, where a detailed plan for RSII's entrance into this sector will be outlined."

Look & Listen at the video on Facebook with outside one of the labs of a compounding pharmacy: https://www.facebook.com/RisingIndiaUSA/?hc_r...mp;fref=nf

1- What is “compounding”?
In general, compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.

2-Why do some patients need compounded drugs?
Sometimes, the health needs of a patient cannot be met by an FDA-approved medication. For example: if a patient has an allergy and needs a medication to be made without a certain dye; or
if an elderly patient or a child can’t swallow a pill and needs a medicine in a liquid form that is not otherwise available.

3-Are compounded drugs approved by the FDA?
Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.
Generally, state boards of pharmacy will continue to have primary responsibility for the day-to-day oversight of state-licensed pharmacies that compound drugs in accordance with the conditions of section 503A of the FDCA, although FDA retains some authority over their operations. However, outsourcing facilities that register under section 503B are regulated by FDA and must comply with CGMP requirements and will be inspected by FDA according to a risk-based schedule.

NOW...OWCP is a pharmaceutical co....that route is so much riskier and cost millions and millions of dollars to do studies and submit to FDA for approval....MOST get denied or fail phase 1 and 2 studies....RSII model has a different set of regulations that are PERFECT for the medical cannabis industry....Revs are instant and their are no FDA guidleines...This is going to be huge...very huge.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 6

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 5

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading

Top 5 Most Recently Viewed Articles

Electra Battery Materials Secures Financing for Cobalt Project

Updated Category News Views 211

Electra Battery Materials Marks Significant Funding Milestone Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) is excited to share the latest developments regarding its cobalt sulfate refinery. The company recently welcomed two Members of Parliament to its site, highlighting the importance of government support in advancing critical mineral projects in...

Continue Reading
Esperion's Approach to Innovating Cholesterol Management

Updated Category News Views 101

Esperion to Share Third Quarter Financial Results Soon Esperion (NASDAQ: ESPR) recently made an announcement regarding its upcoming financial report for the third quarter of 2025. Before the market opens on a Thursday, the company plans to release its financial results, providing insights into its performance and future strategy. Understanding Esperion's Webcast Post the...

Continue Reading
Understanding Summit Materials' Short Interest Trends

Updated Category News Views 204

Investing Insight: Short Interest in Summit Materials Summit Materials has recently reported a notable decline in its short percent of float. The latest statistics indicate that its short interest has decreased by 8.31% since the previous report. Currently, there are 3.93 million shares sold short, representing 3.64% of all shares available for public trading. Given its...

Continue Reading
First European Participants Enrolled in AskBio's PD Gene Therapy Trial

Updated Category News Views 151

Milestone Achieved in Parkinson’s Disease Research AskBio Inc. is making significant strides in the battle against Parkinson’s disease with its novel investigational gene therapy, AB-1005. The company recently announced that the first participants in Europe have been randomized in the REGENERATE-PD trial, a pivotal Phase 2 study aimed at addressing moderate-stage...

Continue Reading
Brookfield's Vision for 2026: Investment Insights and Strategies

Updated Category News Views 200

Brookfield's Investment Outlook for 2026 Brookfield Asset Management has released its investment outlook for the coming period, emphasizing strong currents that are shaping the global economy. These dynamics are preparing the ground for one of the most critical investment landscapes in recent decades. Understanding the Structural Changes Currently, we are witnessing a...

Continue Reading